imatinib mesylate has been researched along with Diabetic Glomerulosclerosis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, JM; Chang, WA; Chen, SC; Hsu, YL; Huang, JC; Hung, WW; Tsai, YC; Wu, LY; Wu, PH | 1 |
| Imada, K; Miura, M; Onaka, T; Sawada, K; Takahashi, N; Yonezawa, A | 1 |
| Allen, TJ; Calkin, AC; Cooper, ME; Jandeleit-Dahm, K; Lassila, M; Seah, KK; Smith, CM | 1 |
| Abou Ayache, R; Bridoux, F; Dreyfus, B; Guilhot, F; Milin, S; Thierry, A; Touchard, G | 1 |
4 other study(ies) available for imatinib mesylate and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
KITLG Promotes Glomerular Endothelial Cell Injury in Diabetic Nephropathy by an Autocrine Effect.
Topics: Albumins; Animals; Biomarkers; Creatinine; Diabetes Mellitus; Diabetic Nephropathies; Endothelial Cells; Humans; Imatinib Mesylate; Kidney Glomerulus; Mice; Mice, Inbred Strains; Proto-Oncogene Proteins c-akt; Stem Cell Factor | 2022 |
Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure.
Topics: Aged; Antineoplastic Agents; Benzamides; Diabetic Nephropathies; Drug Resistance, Neoplasm; Female; Gastrointestinal Hemorrhage; Humans; Imatinib Mesylate; Kidney Failure, Chronic; Leukemia, Myeloid, Chronic-Phase; Lung Diseases, Interstitial; Male; Middle Aged; Nausea; Piperazines; Polycystic Kidney Diseases; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis | 2012 |
Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.
Topics: Animals; Apolipoproteins E; Base Sequence; Benzamides; Biopsy, Needle; Diabetic Nephropathies; Disease Models, Animal; Gene Expression Regulation; Imatinib Mesylate; Immunohistochemistry; Kidney Function Tests; Male; Mice; Mice, Knockout; Molecular Sequence Data; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reference Values; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Transforming Growth Factor beta | 2005 |
Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Topics: Antineoplastic Agents; Benzamides; Diabetic Nephropathies; Female; Humans; Imatinib Mesylate; Kidney Failure, Chronic; Kidney Transplantation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors | 2007 |